Weiss Multi-Strategy Advisers’s Haemonetics HAE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-26,690
Closed -$2.28M 216
2023
Q4
$2.28M Sell
26,690
-5,310
-17% -$459K 0.05% 355
2023
Q3
$2.87M Sell
32,000
-6,625
-17% -$591K 0.07% 326
2023
Q2
$3.29M Sell
38,625
-2,653
-6% -$224K 0.07% 376
2023
Q1
$3.42M Buy
41,278
+13,278
+47% +$1.07M 0.08% 334
2022
Q4
$2.2M Buy
28,000
+2,650
+10% +$213K 0.06% 368
2022
Q3
$1.88M Buy
25,350
+8,850
+54% +$635K 0.05% 411
2022
Q2
$1.07M Buy
16,500
+1,496
+10% +$88.5K 0.03% 474
2022
Q1
$949K Sell
15,004
-2,904
-16% -$158K 0.02% 512
2021
Q4
$950K Buy
17,908
+653
+4% +$39.8K 0.02% 487
2021
Q3
$1.22M Buy
17,255
+2,255
+15% +$142K 0.03% 477
2021
Q2
$1M Buy
+15,000
New +$1.06M 0.02% 490
2021
Q1
Sell
-5,000
Closed -$594K 754
2020
Q4
$594K Sell
5,000
-5,164
-51% -$556K 0.01% 547
2020
Q3
$887K Buy
10,164
+114
+1% +$9.96K 0.02% 435
2020
Q2
$900K Buy
+10,050
New +$1.02M 0.03% 420
2014
Q1
Sell
-5,210
Closed -$219K 1027
2013
Q4
$219K Sell
5,210
-1,590
-23% -$65.4K ﹤0.01% 891
2013
Q3
$271K Buy
+6,800
New +$285K 0.01% 686

Other funds holding HAE

Weiss Multi-Strategy Advisers's HAE Position: Q1 2024 in Review

Weiss Multi-Strategy Advisers sold out of Haemonetics (HAE) in Q1 2024, closing a stake of 26,690 shares — an estimated $2.28M sold.

Weiss Multi-Strategy Advisers first reported a position in HAE in Q3 2013 and held it in 16 quarters. The position peaked at $3.42M in Q1 2023. 298 funds tracked by Wall St. Rank hold HAE as of Q1 2024.

  • Weiss Multi-Strategy Advisers reported no remaining Haemonetics position as of Q1 2024 after selling out during the quarter.
  • Weiss Multi-Strategy Advisers sold 26,690 Haemonetics shares in Q1 2024, an estimated $2.28M.
  • Weiss Multi-Strategy Advisers first reported a position in Haemonetics in Q3 2013 and held it in 16 quarters.
  • Weiss Multi-Strategy Advisers's Haemonetics position peaked at $3.42M in Q1 2023.
  • 298 funds tracked by Wall St. Rank held Haemonetics as of Q1 2024.

Based on Weiss Multi-Strategy Advisers's 13F filing for Q1 2024.